British pharmaceutical giant GlaxoSmithKline announced Wednesday the acquisition of a drug under development to treat a common form of liver disease, in a deal worth up to $2 billion.
This article was originally published on MedicalXpress.com
GSK buys liver disease drug for up to $2 bn
You may also be interested in:
The Latest
Microneedling Services in Edmonton: Benefits, Treatment Cost, and How It Works
Microneedling is a revolutionary skincare treatment that has gained popularity in recent years due to its numerous benefits, including reducing the appearance of scars, wrinkles, and acne, and promoting collagen production. Edmonton, the bustling capital […]
The Latest
Will a nutritional supplement help you run better?
Whether you jog to keep fit or compete in marathons, the physically demanding sport of running can deplete the body of essential nutrients. During a race like a half-marathon, a runner’s metabolism — or ability […]
The Latest
Why stress-related illness is so hard to diagnose, and how a patient-centred playful approach can help
For at least three decades, researchers have gathered evidence that chronic stress puts pressure on the body to constantly adjust itself to restore physiological stability. This process is known as allostatic load and it creates a cascade […]
Read More:
-
There is a nationwide shortage of pediatric specialists, delaying care for many patients. In some cases, children wait weeks or even months for appointments. But [...]
-
Economic disadvantage leaves a biological imprint on children which could last throughout their lifetime, reducing their quality and length of life. These are the findings [...]
-
New research from the Monell Chemical Senses Center and Temple University about nutritional biomarkers using carbon and nitrogen stable isotope ratios showed very different results [...]
